BioCardia, Inc. (BCDA)

Market Cap	9.91M
Revenue (ttm)	477,000
Net Income (ttm)	-11.57M
Shares Out	26.87M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,218
Open	0.379
Previous Close	0.366
Day's Range	0.369 - 0.384
52-Week Range	0.320 - 2.920
Beta	1.49
Analysts	Strong Buy
Price Target	4.00 (+984.01%)
Earnings Date	May 8, 2024

About BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Peter A. Altman Ph.D.
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: BCDA

Financial Performance

In 2023, BioCardia's revenue was $477,000, a decrease of -64.72% compared to the previous year's $1.35 million. Losses were -$11.57 million, -2.82% less than in 2022.

Analyst Forecast

According to one analyst, the rating for BCDA stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(984.01% upside)

Analyst Consensus: Strong Buy